Nonresponse to interferon in chronic hepatitis C: Re-treatment redux

JAMA

Volumn 285, Issue 2, 2001, Pages 212-214

  Koff, R S ^a  

^a University of Massachusetts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RIBAVIRIN;

DRUG EFFICACY; HEPATITIS C; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS TITRATION;

EID: 0035835081     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.2.212     Document Type: Review

References (22)

1. Risk factors for the rising rates of primary liver cancer in the United States
2. Estimating future hepatitis C morbidity, mortality, and costs in the United States
3. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
4. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
5. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
6. Interferon alfa-2b alone or in combination with ribavirin for the treatement of relapse of chronic hepatitis C
7. Retreatment of chronic hepatitis C with concensus interferon
8. Hepatitis C virus resistance to antiviral therapy
9. Hepatitis C virus: Evasion of the interferon-induced antiviral response
10. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials
11. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous IFN therapy: A metaanalysis of controlled and uncontrolled trials
12. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
13. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial
14. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon
15. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C
16. Peginterferon alfa-2a in patients with chronic hepatitis C
17. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
18. Peginterferon atfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial
19. Modeling the impact of interferon alia treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
20. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia
21. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C
22. Design of the HALT-C trial (hepatitis C antiviral long-term treatment to prevent cirrhosis)